During the last 15 years, tremendous efforts have been made toward medical treatment of metastatic renal cell carcinoma (mRCC). Checkpoint inhibitors (CPI) and tyrosine kinase inhibitors (TKI) dominate the therapeutic armamentarium, as a combination of either CPIs or CPI/TKI, while the value of TKI monotherapy is decreasing. With increasing efficiency, however, toxicity also increases. Appropriate management of adverse events is therefore pivotal. Recognizing adverse events, judging their etiology and appropriate management, and sometimes expanding the diagnostics of adverse events are mandatory and demand experience and vigilance. Ultimately, appropriate safety management achieves optimal oncological outcomes and maintains patient quality of life.
Advances in therapy. 2023 Jul 12 [Epub ahead of print]
Philipp Ivanyi, Jonas Paul Wiegmann, Hendrik Eggers, Viktor Grünwald
Department for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Claudia Von Schilling-Center, Comprehensive Cancer Center, Hanover Medical School, OE 6860, Carl-Neuberg Str. 1, 30625, Hanover, Germany. ., Department for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Claudia Von Schilling-Center, Comprehensive Cancer Center, Hanover Medical School, OE 6860, Carl-Neuberg Str. 1, 30625, Hanover, Germany., Department for Urology, Department for Medical Oncology, Chair for Interdisciplinary Uro-Oncology, West-German Cancer Center, University Hospital Essen, Essen, Germany.